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Abstract
Aim Neuroblastoma is a heterogeneous childhood cancer derived from the neural crest. The dual cell identities of neu-
roblastoma include Mesenchymal (MES) and Adrenergic (ADRN). These identities are conferred by a small set of tightly-
regulated transcription factors (TFs) binding super enhancers, collectively forming core regulatory circuitries (CRCs). The 
purpose of this study was to gain a deep understanding of the role of MES and ADRN TFs in neuroblastoma and other 
cancers as potential indicators of disease prognosis, progression, and relapse.
Methods To that end, we first investigated the expression and mutational profile of MES and ADRN TFs in neuroblastoma. 
Moreover, we established their correlation with neuroblastoma risk groups and overall survival while establishing their 
extended networks with long non-coding RNAs (lncRNAs). Furthermore, we analysed the pan-cancer expression and 
mutational profile of these TFs and their correlation with patient survival and finally their network connectivity, using a 
panel of bioinformatic tools including GEPIA2, human pathology atlas, TIMER2, Omicsnet, and Cytoscape.
Results We show the association of multiple MES and ADRN TFs with neuroblastoma risk groups and overall survival and 
find significantly higher expression of various MES and ADRN TFs compared to normal tissues and their association with 
overall survival and disease-free survival in multiple cancers. Moreover, we report the strong correlation of the expression 
of these TFs with the infiltration of stromal and immune cells in the tumour microenvironment and with stemness and 
metastasis-related genes. Furthermore, we reveal extended pan-cancer networks comprising these TFs that influence 
the tumour microenvironment and metastasis and may be useful indicators of cancer prognosis and patient survival.
Conclusion Our meta-analysis shows the significance of MES and ADRN TFs as indicators of patient prognosis and the 
putative utility of these TFs as potential novel biomarkers.
Keywords Core regulatory circuitry · Neuroblastoma · Solid cancers · Tumour microenvironment · Gene networks · 
Differentiation
Leila Jahangiri and Perla Pucci contributed equally to this study
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s12672- 021- 
00452-3.
 * Leila Jahangiri, leila.jahangiri@bcu.ac.uk; Perla Pucci, pp504@cam.ac.uk; Tala Ishola, tala.ishola@bcu.ac.uk; Joao Pereira, jdpereira@
cantab.net; Megan L. Cavanagh, megan.cavanagh@mail.bcu.ac.uk; Suzanne D. Turner, sdt36@cam.ac.uk | 1Department of Life 
Sciences, Birmingham City University, Birmingham, UK. 2School of Science & Technology, Nottingham Trent University, Clifton Lane, 
Nottingham NG11 8NS, UK. 3Division of Cellular and Molecular Pathology, Addenbrooke’s Hospital, University of Cambridge, Cambridge, 
UK. 4Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. 5CEITEC, Masaryk University, Brno, Czech Republic.
Vol:.(1234567890)
Research Discover Oncology           (2021) 12:56  | https://doi.org/10.1007/s12672-021-00452-3
1 3
Abbreviations
ACC  Adrenocortical carcinoma
BLCA  Bladder Urothelial Carcinoma
BRCA  Breast invasive carcinoma
CESC  Cervical squamous cell carcinoma and endocervical adenocarcinoma
CHOL  Cholangiocarcinoma
COAD  Colon adenocarcinoma
CRC  Core regulatory circuitry
DLBC  Lymphoid Neoplasm Diffuse Large B-cell Lymphoma
DFS  Disease-free survival
ECs  Endothelial cells
EFS  Event-free survival
EMT  Epithelial to mesenchymal transition
ESCA  Oesophageal carcinoma
GBM  Glioblastoma multiforme
HNSC  Head and Neck squamous cell carcinoma
HR  Hazard risk
INRG  International Neuroblastoma Risk Group
KICH  Kidney Chromophobe
KIRC  Kidney renal clear cell carcinoma
KIRP  Kidney renal papillary cell carcinoma
LAML  Acute Myeloid Leukaemia
LGG  Brain Lower Grade Glioma
LIHC  Liver hepatocellular carcinoma
LncRNAs  Long non-coding RNAs
LUAD  Lung adenocarcinoma
LUSC  Lung squamous cell carcinoma
MESO  Mesothelioma
miRNAs  MicroRNAs
MRD  Minimal residual disease
OS  Overall survival
OV  Ovarian serous cystadenocarcinoma
PAAD  Pancreatic adenocarcinoma
PCPG  Pheochromocytoma and Paraganglioma
PRAD  Prostate adenocarcinoma
READ  Rectum adenocarcinoma
RFS  Relapse-free survival
RPKM  Reads per kilobase of transcripts per million reads
SARC  Sarcoma
SKCM  Skin Cutaneous Melanoma
STAD  Stomach adenocarcinoma
TAMs  Tumour associated macrophages
TFs  Transcription factors
TGCT  Testicular Germ Cell Tumour
THCA  Thyroid carcinoma
TME  Tumour microenvironment
TPM  Transcript count per million
Treg  T regulatory cells
UCEC  Uterine Corpus Endometrial Carcinoma
UCS  Uterine Carcinosarcoma
UVM  Uveal Melanoma
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1 Introduction
Neuroblastoma (NB) is a paediatric malignancy that accounts for circa 15% of cancer-related paediatric deaths [1]. 
Based on clinical presentation, behaviour, and therapy response, this disease is classified into five stages (1–4 and 
4S), with advanced stages (3 and 4) displaying metastatic behaviour [1, 2]. Risk groups are classified according to 
a variety of criteria, which include MYCN amplification status, age, disease stage, histologic characteristics, grade 
of tumour, ploidy, and chromosome 11q structural alterations. For instance, the presence of MYCN amplification, 
poor differentiation status, diploidy, and chromosome 11q aberrations are associated with unfavourable outcomes. 
Indeed, NB cases with MYCN amplification, representing ~ 50% of patients in high-risk groups, have a 5-year survival 
of 40–50% [1–3]. NB is formed of cells of the neural crest that are halted in their developmental stages and fail to 
differentiate [4]. Previous studies have identified the dominance of epigenetic regulation in this form of cancer, estab-
lishing tumour identities inclusive of two cell types. Accordingly, tumours are classified by the prevalence of neural 
crest migratory (mesenchymal, MES) and committed adrenergic (ADRN) cellular sub-types [5–7]. Notably, cell identity 
can be conferred by tightly regulated transcription factors (TFs) which engage super enhancers genome-wide, col-
lectively forming core regulatory circuitries (CRCs) [8–11]. These TFs self-regulate and bind to regulatory regions of 
other CRC TFs, driving lineage-specific gene expression, hence cell identity [8–11]. NB ADRN subtype-specific genes 
include PHOX2B, PHOX2A, and DBH, while the MES subtype expresses high levels of SNAI2, FN1, and VIM [5–7]. The 
extended MES and ADRN CRCs comprise 485 and 369 genes, respectively, a list further refined by van Groningen 
and colleagues to just 20 MES and 18 ADRN CRC TFs that constitute the core TFs [5, 6]. The role of these TFs in NB 
development and maintenance of their normal cell counterparts has been studied to a certain extent. For instance, 
the ADRN CRC TF, ASCL1, a bHLH TF is implicated in cell growth and differentiation arrest, while GATA3 is a biomarker 
linked to suppression of differentiation. Furthermore, ISL1 suppresses genes that are involved in the process of NB 
differentiation [12–14]. Conversely, PHOX2A and PHOX2B are indicated in neural progenitor differentiation [15], while 
HAND1, SOX11, and TFAP2B are crucial for differentiation towards catecholaminergic, sympatho-adrenergic, and 
adrenergic fates, respectively [16–18]. Hence, these TFs not only play a major role in the developmental processes 
of neural differentiation toward specific sympathoadrenal fates, processes that diverge from their normal develop-
mental programme in NB, but also govern the establishment of MES and ADRN identities in NB.
From the viewpoint of patient prognosis, the association of subsets of these TFs with NB risk groups, patient survival, 
prognostic and diagnostic indications in NB has been investigated [13, 19–26], although not extensively for all of the TFs. 
Furthermore, many of these CRC TFs may be implicated in gene regulatory networks, molecular pathways, and signalling 
cascades common to various cancers. Therefore, they may have prognostic value in NB and form extended networks 
with long non-coding RNAs (lncRNAs). LncRNAs are often upregulated in cancer and are increasingly characterised as 
potential prognostic and diagnostic biomarkers and therapeutic targets for several cancers, including NB [20]. Moreover, 
we extended these studies to their expression and association with patient survival across various cancers.
In NB, T-cell infiltration to the tumour microenvironment (TME), correlates with enhanced patient overall survival (OS). 
Specifically, the expression and activation of MYCN, ASCL1, and SOX11 are inversely correlated with T-cell infiltration 
in NB and correlate with patient OS [27], supporting the significance of these TFs in the NB TME. Notably, similar asso-
ciations between MES and ADRN TFs with the infiltration of cancer-associated fibroblasts (CAFs) of the TME implicate 
these TFs in pro-tumourigenic remodelling of the TME in cancers [28–31]. Furthermore, tightly associated with these 
events are epithelial to mesenchymal transition (EMT) and cancer stemness markers, including CD44, CDH1, CDH2, FN1, 
FOXC2, NANOG, SOX2, TWIST1, and VIM that are triggered by hypoxia in the TME [32, 33]. Given this background, we 
were intrigued to conduct a comprehensive pan-cancer assessment of the association of these TFs with the infiltration of 
tumour-associated immune and stromal cells in the TME. We also focused on the link between these TFs with markers of 
EMT and stemness and the resulting extended mRNA-microRNA (miRNA) regulatory networks they form. For this, we have 
leveraged multiple tools including cBioPortal, GEPIA2, the human pathology atlas, TIMER2, Omicsnet, and Cystoscape. 
We report the misregulation of a subset of both MES and ADRN TFs in NB high-risk groups, their correlation with patient 
survival, and intricate gene regulatory networks. In a further pan-cancer approach, we report the high expression of 
MES and ADRN TFs in multiple cancer types compared to normal tissue, the association of this expression pattern with 
prognosis, and altered OS and disease-free survival (DFS). Furthermore, we identify an association between cancer-
associated fibroblasts (CAFs), T regulatory cells (Tregs), B cells, gamma-delta T cells, endothelial cells (ECs) of the TME, and 
markers of EMT and stemness with the expression of MES and ADRN TFs and their connectivity with other cancers and TF 
networks. Finally, we report the role of MES and ADRN TFs as indicators of patient survival in NB and other solid cancers.
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2  Materials and methods
2.1  Gene Ontology of MES and ADRN genes and their correlation with NB risk groups
A list of 485 MES and 369 ADRN genes was subjected to Gene Ontology enrichment analysis using PANTHER (Addi-
tional file 1: Materials S1) [5–7, 34]. Despite the paucity of somatic mutations in NB and the importance of epigenetic 
regulation in this cancer [35], we subjected 854 MES and ADRN extended CRC network genes to the cBioportal genetic 
alteration tool, having selected 1472 NB patient samples including AMC Amsterdam, Nature 2012 (87 samples), Broad, 
Nature Genetics 2013 (240 samples), Broad, Nature 2015 (56 samples) and Paediatric NB, TARGET, 2018 (1089 samples) 
(Additional file 1: Materials S1) [36, 37].
Furthermore, we narrowed our analysis to the 20 MES and 18 ADRNs TFs, as reported by van Groningen and col-
leagues, since these TFs comprise the core defining factors of MES and ADRN identities and include ELK4, CREG1, DCAF6, 
ID1, SMAD3, SIX4, SIX1, MAML2, NOTCH2, CBFB, IFI16, ZNF217, EGR3, ZFP36L1, WWTR1, PRRX1, SOX9, MEOX1, MEOX2, 
AEBP1, for MES and ZNF536, PHOX2A, HAND1, ASCL1, KLF13, SOX11, GATA2, GATA3, KLF7, EYA1, TFAP2B, ISL1, HEY1, SIX3, 
DACH1, PHOX2B, PBX3, SATB1 for ADRN [5–7]. For simplicity, hereafter, we have referred to these TFs as “the 38 TFs”. To 
assess the correlation of MES and ADRN TF expression with low/intermediate and high-risk groups of NB patients, we 
used TARGET data deposited to cBioPortal. Low-risk NB patients were infants younger than 18 months lacking MYCN 
amplification with either localised or metastatic disease. Half of the high-risk cases displayed MYCN amplification, while 
the remaining half may have displayed a combination of other high-risk associated criteria [1]. In addition, event-free 
survival (EFS), the time after the primary treatment in which the patient did not experience any events that the treat-
ment aimed to delay or prevent, with a cut-off of 75–85%, 50–75%, and < 50% were defined as low, intermediate, and 
high-risk NB cases, respectively [3].
The expression correlation analyses were performed on cBioPortal RNA sequencing data of 143 NB patient samples 
(TARGET, 2018) for the 38 MES and ADRN genes. The top 20 positively correlated genes were shortlisted for each of the 
MES and ADRN genes in order to select the strongest co-expression correlations. Amongst them, 9 lncRNAs positively 
correlated with 10 ADRN and MES genes, most of which with strong correlations (Spearman > 0.7).
The correlation between TFs and lncRNAs expression with patient OS was obtained from cBioPortal and the follow-
ing method was used: the samples were grouped based on the upregulation (high) or downregulation (low) of each 
queried gene, using z-score equals 1 or a consistent criterion of at least 10% of samples displaying upregulation and 
relevant survival plots were generated. In this statistical test, the variable of interest was the time elapsed before event 
occurrence. Accordingly, increased and decreased OS accounted for an elongated or shortened duration for which the 
patient was alive.
2.2  Gene expression analysis
Expression profiles of the 38 TFs were investigated in more than 30 cancer types using TCGA (tumour) and matching 
normal tissue data using the GEPIA2 expression DIY module [38]. This programme collated expression data from tumour 
and normal tissue as the log2 fold change (log2FC) with a cut-off of 1 and p < 0.01 and used one-way ANOVA to assign 
statistical significance. Cancer name abbreviations have been provided in the list of abbreviations. We also linked the 
expression of the 38 TFs in over 30 cancer types with their mutational profile in these cancers using cBioPortal (Additional 
file 1: Materials S2).
2.3  Independent prognostic summary
The 38 TFs were further studied using TIMER2 across over 30 cancer types to determine the clinical relevance of their 
expression [39, 40]. This tool used a Cox proportional hazard (PH) evaluation to assess the clinical significance of the 
expression of a gene in a cancer type and provided Kaplan Meier OS analyses.
Furthermore, OS and EFS maps and Kaplan Meier curves were generated using the GEPIA2 tool, which also used the 
COX PH model. OS and EFS represented the time for which a patient was alive and the duration for which the patient 
did not display signs/ symptoms of cancer, respectively. The median expression was utilised as a cut-off between low 
and high expression, with the number of patient tissue samples per cancer type reported in Additional file 1: Materials 
S3 (although this tool did not specify whether these samples were primary or secondary tumours).
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2.4  The prognostic value of expression of the 38 TFs
The prognostic significance of the 38 TFs was investigated across multiple cancer types using the human pathology atlas 
(https:// www. prote inatl as. org/). The classification of favourable and unfavourable prognoses in this database is based 
on Kaplan Meier survival analyses.
2.5  The correlation between immune cell infiltration and gene expression across cancer types
The 38 TFs were further studied using TIMER2 for immune cell infiltration correlations for over 30 cancer types [39, 40]. 
TIMER2 utilised deconvolution statistical methods to determine the distribution of tumour infiltrating cells in the context 
of TCGA gene expression profiles. Partial Spearman’s correlation allowed for the assessment of immune cell infiltration 
with adjustment for tumour purity. The number of patient tissue samples utilised for each cancer is reported in Additional 
file 1: Materials S4 (this tool did not specify whether these samples were primary or secondary tumours).
2.6  The association of the 38 TFs with EMT and cancer cell genes across cancer types
The TIMER2 gene correlation module was used to establish the association of MES and ADRN TFs with a list of genes 
involved in EMT and cancer stemness markers including CD44, CDH1, CDH2, FN1, FOXC2, NANOG, SOX2, TWIST1, and 
VIM [32].
2.7  Omicsnet, Cytoscape, and dbCorC database for network analysis for the 38 TFs
Omicsnet was used to investigate different types of network interactions [41]. We used the 38 TF gene IDs and built 
networks using default settings (transcription factor gene interactome; TGI) and 2D visualisation. TGI utilised the infor-
mation in TRRUST, JASPAR, and ENCODE databases and the network was subjected to enrichment analysis by selecting 
the KEGG gene option. Further, we utilised Cytoscape 3.8.0 [42] and NDEx v2.4.5 [43] to investigate and visualise the 
mRNA versus miRNA networks of GATA3 and SOX9 in hepatocellular cancer (HCC) and diffuse large B cell lymphoma 
(DLBCL), respectively.
Finally, the dbCoRC database was utilised to integrate the mRNA expression of core TFs with their reconstructed cir-
cuitry. This database archived information about CRC components, including CRC TFs, binding sites for TFs, and super 
enhancer genomic coordinates, allowing for the interrogation of specific TFs in CRCs of defined cell types and the sub-
sequent visualisation of the CRCs constructed [44].
3  Results
3.1  MES and ADRN TFs are associated with NB risk groups, patient survival, and lncRNA expression
Gene Ontology analysis was conducted on the 485 MES and 369 ADRN genes previously reported to define the respec-
tive NB cell subtypes [5–7]. Analysis of ADRN genes yielded the term ‘enrichment for adrenaline and dopamine-related 
pathways’, while for MES, terms such as ‘angiogenesis’, ‘cadherin’, ‘PDGF’, ‘integrin’, ‘JAK/STAT signalling pathways’, and 
‘inflammatory pathways’ were obtained (Additional file 1: Materials S1) [45].
cBioPortal analysis was conducted of 1472 individual NB primary patient tissues previously included in large studies 
(i.e., Neuroblastoma (AMC Amsterdam), Neuroblastoma (Broad 2013 and 2015), Paediatric Neuroblastoma (TARGET)) 
using the 485 MES and 369 ADRN associated genes revealing genetic alterations of putative drivers, e.g., EPHA3 A629 
splice mutation, FGFR1 N546K missense mutation and LATS2 P479_A480insPP (Additional file 1: Materials S1). EPHA3 A629 
splice mutation, per se, was identified in sample NBL44 data deposited to cBioPortal and is likely oncogenic, while FGFR1 
N546K missense mutation was identified in TARGET-30-PARCRR sample revealing an allele frequency of 0.47, represented 
in less than 1% of the TARGET cohort. Finally, LATS2 P479_A480insPP identified in NBL35 sample is an in-frame mutation 
that is predicted to be oncogenic. Apart from these predicted drivers, we have also linked each genetic alteration with 
unknown significance reported in Additional file 1: Materials S1, with specific identifiers, which will allow obtaining more 
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information about the alteration and the corresponding patient data. For instance, a missense mutation of unknown 
significance, DLC1 S978C, is linked to TARGET-30-PAMVLG sample. The inspection of this alteration using cBioportal reveals 
that the allelic frequency is 0.55 and specific clinical information about the corresponding patient from which this sample 
was obtained. These data are significant, since, apart from MYCN and ALK genetic alterations, others, especially those 
with a putative oncogenic driver description, have not previously been described in NB. These discoveries could provide 
a blueprint for future diagnostic and therapeutic endeavours.
Given these results, we sought to determine correlations between these TFs, risk groups, and patient survival. Multiple 
criteria influence high-risk stratification in NB, and for clarity, we have referred to the International Neuroblastoma Risk 
Group (INRG) classification, where EFS cut-offs are 75–85% (low-risk), 50–75% (intermediate-risk), and < 50% (high-risk) 
[3].
Upon correlating the refined list of 38 TFs with risk groups in NB patient samples, we report that 8 ADRN and 8 MES 
TFs were significantly up- or downregulated in high-risk NB, as defined by the previously mentioned parameters (Fig. 1A, 
B) [3]. These TFs include, for the ADRN group, SATB1, GATA2, TFAP2B, KLF13, KLF7, and PBX3 that were downregulated in 
the NB high-risk group (p<0.0001, 0.0002, 0.0001, 0.0141, 0.0002, and 0.028, respectively). Conversely, SIX3 and GATA3 
were upregulated in this group (p = 0.0133, not significant, respectively) (Fig. 1A).
Among the MES genes, MEOX1, CBFB and DCAF6 were downregulated, (p = 0.046, 0.0001 and 0.0001, respectively), 
while SMAD3, ID1, SOX11, ZNF217 and EGR3 were upregulated in NB high-risk groups (p = 0.009, 0.0115, 0.014, 0.021 
and 0.035 respectively) (Fig. 1B). Therefore, these TFs (isolated or in clusters) might represent biomarkers for assigning 
Fig. 1  ADRN and MES TF expression correlates with NB risk group and OS. A 8 ADRN TFs significantly correlate with NB risk (student t-test). 
SATB1, GATA2, TFAP2B, KLF13, KLF7 and PBX3 are downregulated in high-risk NB cases, while SIX3 and GATA3 are upregulated in this group 
(although the latter is not significant). B 8 MES TFs significantly correlate with NB risk (student t-test). MEOX1, CBFB and DCAF6 are down-
regulated in high-risk NB cases, while SMAD3, ID1, SOX11, ZNF217 and EGR3 are upregulated in the high NB risk group. Data shown are repre-
sentative of 143 samples from NB tissue processed for RNA sequencing (TARGET, 2018). Low, intermediate, and high-risk cases have an EFS 
of 75–85%, 50–75% or < 50% respectively. NS: not significant
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patients to risk groups for treatment stratification. Data shown in Fig. 1 are representative of 143 NB tissue samples 
analysed by RNA sequencing (TARGET, 2018).
Given these significant findings, we sought to follow up these results by assessing the correlation of these TFs 
with NB prognosis and patient survival. Of the CRC TF genes, 6 were associated with NB patient OS, based on reads 
per kilobase of transcripts per million reads (RPKM) values of RNA sequencing (Additional file 2: Fig. S1A) or Agilent 
microarray data (Additional file 2: Fig. S1B) deposited to cBioportal. For instance, KLF7 and TFAP2B were upregulated 
in patients with increased survival. In contrast, HAND1, EGR3, PBX3, and ASCL1 were upregulated in patients with 
reduced survival (although both TFAP2B and HAND1 show trends) (Additional file 2: Fig. S1A, B). Notably, KLF7 was 
associated with better survival outcomes based on both RNA sequencing and microarray analyses (Additional file 2: 
Fig. S1A, B). These data suggest a significant association of expression of these TFs with NB high-risk groups and 
their association with patient survival outcomes. However, these data will need to be validated in preclinical models 
and in a prospective clinical trial scenario, whereby a predictive outcome algorithm can be developed. These find-
ings lay the groundwork for potential new biomarker discovery in both MES and ADRN subtypes of NB. A further 
factor that affects poor prognosis in NB is MYCN amplification status. Since a component of MYCN regulation and 
NB stratification depends on interactions with lncRNAs, we investigated potential links between lncRNAs with MES 
and ADRN TFs and NB features [46]
The correlation analyses of Spearman and Pearson found lncRNAs that positively correlate with MES and ADRN CRC 
genes (Fig. 2A, B and Additional file 2: Fig. S1C). For instance, MEOX2, SIX1, GATA2, TFAP2B, GATA3, SIX3, PHOX2A, GATA2, 
SATB1, and TFAP2B expression positively correlate with LINC02587, EMX2OS, DBH-AS1, DBH-AS1, GATA3-AS1, SIX3-AS1, 
MORC2-AS1, GATA2-AS1, KLF9-AS1, and LIFR-AS1, respectively. Notably, DBH-AS1 expression strongly correlates with 
GATA2 (Spearman = 0.64, p = 2.59E-17) and TFAPB2 (Spearman = 0.72, p = 6.17E−24) (Fig. 2B).
Two other lncRNAs of particular interest were also identified, SIX3-AS1 and GATA3-AS1, since their expression posi-
tively correlated with SIX3 and GATA3, respectively (Fig. 2B). Both were upregulated in the NB high-risk group (SIX3-
AS1 p = 0.0298 and GATA3-AS1 p = 0.015) (Fig. 2C). GATA3-AS1 was associated with reduced survival (p = 0.024), even 
though for SIX3-AS1 the log-rank test was not significant and did not reveal an association with patient OS (Fig. 2D).
DBH-AS1 expression was also decreased in the NB high-risk group (p < 0.0001) (Fig. 2C) and was upregulated in 
patients with increased survival, although this result was not statistically significant (as defined in the Methods sec-
tion, log-rank Test (p = 0.0642) (Fig. 2D).
GATA2-AS1 also positively correlated with the ADRN TF GATA2 (Spearman = 0.71, p = 4.10E−23) (Additional file 2: 
Fig. S1C). The expression of GATA2-AS1 in risk groups was not different (p = not significant) (Fig. 2C), while it was sig-
nificantly associated with reduced OS (log-rank test p = 0.039) (Fig. 2D). GATA2-AS1, GATA3-AS1, and SIX3-AS1 survival 
data are reported from RNA sequencing of 143 NB patient tissues (TARGET, 2018), while DBH-AS1 survival data are 
reported from 249 Agilent microarray analyses of NB samples (TARGET, 2018).
Other lncRNA, such as LIFR-AS1 and KIF9-AS1, were downregulated in high-risk NB (p < 0.0001 and p < 0.0001, 
respectively) (Additional file 2: Fig. S1D). All the expression data presented for both TFs and lncRNAs and their NB risk 
correlation are displayed as RNA sequencing RPKM values. These findings suggested that MES and ADRN TFs are co-
expressed with lncRNAs and display similar association patterns with NB risk and patient survival. Notably, lncRNAs 
can interact with TFs, mostly by stabilising them and promoting their downstream activity [47].
Accordingly, DBH-AS1 has been linked to viral-mediated hepatocellular carcinoma [48], while GATA3-AS1 is asso-
ciated with poor prognosis in breast cancer via the GATA3-AS1/miR-495-3p/CENPU axis [49]. Furthermore, LIFR-AS1 
regulates invasion and metastasis in thyroid cancers [50], while the downregulation of EMX2OS is associated with 
poor patient prognosis in clear cell carcinoma of the kidney [51]. In addition, the association of these lncRNAs with 
the 38 TFs in NB and other cancers led us to profile the role of these TFs and their extended gene networks in cancers.
3.2  Gene expression analysis across cancer types using GEPIA2 shows that MES and ADRN TFs are widely 
expressed in cancers
The expression of 20 MES and 18 ADRN CRC associated genes were analysed in over 30 cancer types using GEPIA2. 
Of the 20 MES TFs 11, 6, 16, 12, and 14 were significantly overexpressed in DLBCL, oesophageal squamous cell carci-
noma (ESCA), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), and thymoma (THYM) patient 
tumour samples, respectively, compared to matched healthy samples (Fig. 3A). For example, for DLBCL, PAAD, THYM, 
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and STAD, PRRX1 showed significantly higher expression levels in tumour compared to matched normal tissue (p < 
0.01) (Fig. 3B, C.
Furthermore, of the 18 ADRN TFs 4, 5, and 8 were significantly overexpressed in glioblastoma multiforme (GBM), low-
grade glioma (LGG), and THYM, respectively (Fig. 3D). For instance, ASCl1 displayed significantly higher expression over 
normal tissue samples in GBM, LGG, and THYM (p < 0.01) (Fig. 3E, F) [52].
In addition, we linked the expression of the 38 TFs in over 30 cancer types with their mutational profile in these can-
cers (Additional file 1: Materials S2). For instance, we have displayed up- or downregulation of the TF genes based on 
the data presented in Fig. 3 and we have linked this information with various patient sample mutations for that cancer 
type obtained from cBioportal. Notably, GATA3 is upregulated in BRCA and we linked this to multiple putative driver 
Fig. 2  LncRNAs are co-expressed with MES and ADRN TFs and are associated with risk groups and survival of NB patients. A, B 6 TFs posi-
tively correlate with 6 lncRNAs, obtained from RNA sequencing data from 143 NB patient tissue samples (TARGET, 2018) (2 lncRNAs for MES 
(A) and 4 for ADRN (B) TFs). C, D LncRNAs are associated with NB risk group; for instance, GATA3-AS1 and SIX3-AS1 are overexpressed in high-
risk NB (C) and survival in the same cohorts of patients. GATA3-AS1 and SIX3-AS1 are also upregulated in patients with lower OS, despite the 
latter not being significant (D) (red and blue lines represent increased and reduced expression, respectively). However, GATA2-AS1 expres-
sion is not associated with NB groups, while it is upregulated in patients with reduced survival. GATA2-AS1, GATA3-AS1 and SIX3-AS1 survival 
data were obtained from RNA sequencing of 143 NB patient tissue, and DBH-AS1 survival data were reported from Agilent microarray of 249 
NB samples (TARGET, 2018). Statistics was calculated on mean ± SEM with student`s t test in (C). NS: not significant, SEM: standard error of 
mean
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mutations including GATA3 M293K, GATA3 S402Lfs*105, GATA3 F430Lfs*45, GATA3 L396Pfs*111, GATA3 P408Afs*99. This 
observation also applied to STAD in which we linked the upregulation of GATA3 with some driver mutations including 
GATA3 S237Afs*28 and GATA3 S237Afs*28, although these links do not necessarily convey causative effects. These results 
suggest a significant role for these TFs in a wider range of cancers.
3.3  TIMER2 analysis shows an association of the 38 TFs with patient survival across cancer types
Kaplan Meier survival analysis was conducted for 20 MES and 18 ADRN genes in over 30 cancer types and their subtypes 
using the TIMER 2 gene_outcome module. This tool uses a Cox proportional hazard (PH) to assess the clinical signifi-
cance of the expression of a gene in a cancer type in the form of Kaplan Meier OS analysis (Additional file 1: Materials 
S3). For example, for 290 Kidney renal papillary cell carcinoma (KIRP) and 545 Uterine corpus endometrial carcinoma 
(UCEC) patients, the expression of 16/38 and 12/38 genes respectively (e.g., CREG1, SIX1, and MEOX1), was linked with 
a significantly higher risk and a resulting reduced OS (p < 0.05, Spearman’s p > 0) (Additional file 1: Materials S3). For 
instance, the cumulative survival for KIRP and UCEC patients expressing CREG1 (HR = 1.52, p = 0.0217), SIX1 (HR = 2.04, 
p = 0.00046), and MEOX1 (HR = 2.25, p = 0.00098) was significantly reduced. Similarly, cumulative survival was reduced 
for UCEC patients, expressing CREG1 (HR = 1.32, p = 0.048), SIX1 (HR = 1.85, p = 0.0001), and MEOX1 (HR=1.43, p=0.0079) 
(Fig. 4A, B. These results suggest that the 38 TFs are associated with patient survival in a wide range of cancers, highlight-
ing overlapping mechanisms, processes, and gene networks and indicating that these could be used as biomarkers for 
outcome for a range of cancers.
Indeed, considering GEPIA2, survival maps for OS and DFS were generated for the 20 MES and 18 ADRN TFs over 30 
cancer types (Additional file 3: Fig. S2 and Additional file 4: Fig. 3, respectively). These analyses revealed an association 
of the expression of these genes with OS and DFS (Additional file 3: Fig. S2 and Additional file 4: Fig. 3). For example, 
significantly higher risk and consequent reduced OS and DFS were detected for KIRP patients expressing MEOX1 and 
MEOX2 (Additional file 3: Fig. S2) [53]. A similar result was also found for adrenocortical adenocarcinoma (ACC) patients 
expressing GATA3, GATA2, and SOX11 (Additional file 4: Fig. S3) [54].
Furthermore, OS and DFS for ACC patients expressing CBFB (HR = 7.5, log-rank test p = 4.9E−06 and HR = 3.7, log-rank 
test p = 0.00023) were reduced (Fig. 4C, top and bottom). Similarly, OS and DFS for ACC patients expressing SOX11 (HR 
= 5.2, log-rank test p = 0.00032 and HR = 3.7, log-rank test p = 0.00037) (Fig. 4D, top and bottom) and ISL1 (HR = 6.3, log-
rank test p =4.4E−05 and HR = 3.7, log-rank test p = 0.00031) were also reduced (Fig. 4E, top and bottom). These data 
reveal a lower OS and DFS for ACC patients expressing CBFB, SOX11, and ISl1 individually, demonstrating the significance 
of these genes not only in NB but also other solid cancers. Given these results, we sought to investigate the association 
of these TFs with patient prognosis using other databases.
3.4  Human pathology atlas analysis of the 38 TFs shows their association with prognosis in cancers
We found an association of the 38 TFs with prognosis (both favourable and unfavourable) in various cancers including 
renal, lung, pancreatic, endometrial, ovarian, liver, breast, glial, urothelial, and melanoma (Fig. 5A). For instance, ELK4, 
CBFB, IFI16, PRRX1, AEBP1, and GATA3 expression was associated with an unfavourable outcome in renal cancer reveal-
ing the significance of these TFs (pink and blue colours represent unfavourable and favourable prognosis, respectively) 
[55] (Fig. 5A).
Further to the association of expression of these TFs with patient survival, previous studies have linked their expression 
with various immune cells in the TME [27], leading us to address the impact of MES and ADRN TFs on the TME.
3.5  Immune cell infiltration correlates with gene expression across cancer types
Using TIMER2 to associate gene expression with immune cell infiltration, we compared Tregs, CAFs, ECs, B cells, and 
gamma-delta T cells with 20 MES and 18 ADRN genes for KIRP, ACC, DLBCL, PAAD, THYM, STAD, and GBM adjusting for 
tumour purity. We found a strong positive association (p < 0.05, Spearman’s Rho > 0) between the expression of multiple 
MES and ADRN TFs with the infiltration of CAFs, ECs, and B cells in KIRP and PAAD, while this only applied to CAFs and 
ECs in STAD and THYM (Additional file 1: Materials S4). Further, the expression of these TFs in ACC and DLBCL showed a 
negative association with Treg cells (p < 0.05, Spearman’s Rho < 0), while the picture for gamma-delta T cells was mixed 
(Additional file 1: Materials S4).
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A positive association of expression of EGR3 with CAFs in KIRP (p = 7.67E−08, Spearmann’s Rho = 0.327), PAAD (p = 
2.54E−05, Spearmann’s Rho=0.316) and STAD (p = 1.24E−10, Spearmann’s Rho = 0.323) was detected (Fig. 5B, D). These 
results suggest that the expression of EGR3 in KIRP, PAAD, and STAD shows a strong positive correlation with TME ele-
ments, including stromal and immune cells [56]. Accordingly, the interaction of stromal cells such as CAFs with tumour 
cells in the TME can shape the immunosuppressive microenvironment and tumour-promoting phenotypes and poten-
tially inform on therapeutic strategies that aim to reverse CAF-mediated immunosuppression [57]. Hence, the positive 
association of EGR3 gene expression with CAFs in these cancers suggests the contribution of this gene to promoting the 
immunosuppressive roles of CAFs, while negative correlations obtained for Tregs in DLCBCL would suggest the reverse. 
Moreover, different components of the TME, including tumour-associated macrophages (TAMs), induce EMT and cancer 
cell migration, while EMT, chiefly triggered by hypoxia can activate stemness factors [33]. Hence, we sought to understand 
the influence of these TFs on the occurrence of EMT and the expression of stemness factors.
3.6  MES and ADRN TFs are strongly associated with EMT and stemness factors across cancers
Given the link between MES and ADRN TFs and cancer cell migration and the activation of stemness factors [33, 57], we 
used the TIMER2 gene correlation module to establish such associations, detailed further in Additional file 1: Materials 
S5. For example, a positive correlation with all markers tested including CD44, CDH1, CDH2, FN1, FOXC2, NANOG, SOX2, 
TWIST1, and VIM was observed with the following MES and ADRN TFs: SMAD3, CBFB, ZFP36L, KLF7, DACH1, and SATB1 in 
liver hepatocellular carcinoma (LIHC). This positive association implies that SMAD3 may contribute to EMT and stemness 
programmes in these cancers, potentially contributing to their aggressiveness and metastatic potential. Previous stud-
ies reported the role of TGF-β/SMAD signalling in inducing both stemness markers and EMT in prostate cancer cells by 
post-transcriptional modification of CD44 [58]. These findings collectively suggest that MES and ADRN TFs also show 
a positive association with genes involved in EMT and cancer stemness characteristics in other solid cancers. Thus, we 
compared the extended network comprising TF mRNAs and miRNAs that influence the TME, EMT, stemness markers, 
and aggressive behaviour in cancers.
3.7  Analysis of TF‑gene networks, integration, and visualisation of network data shows that these extended 
networks influenced the TME and cancer progression
We sought to determine the extended networks of the 38 TFs and miRNA in impacting the TME, progression, and aggres-
sive behaviour of cancers by using software packages including Omicsnet, Cytoscape, and dbCoRC. GATA3 and GATA2 
displayed the highest degree of connectivity with 38 and 19 connections, respectively (Fig. 6A), and KEGG gene enrich-
ment analysis revealed enrichment for immunity functions and processes, and miRNA in cancer terms (Fig. 6B). SATB1 also 
showed a degree of connectivity of 15 (not shown in Fig. 6B to improve the legibility of the network). In addition, MES 
TFs, SMAD3, SOX9, WWTR1, and IFI16 had 32, 23, 6, and 5 connections, respectively (Fig. 6C), and KEGG gene enrichment 
analysis revealed enrichment for ‘breast cancer’, ‘prostate cancer’, and ‘hepatocellular carcinoma’ processes in addition 
to ‘miRNA in cancer’ terms (Fig. 6D). This analysis suggests that the extended network of TF-gene interactomes for MES 
and ADRN TFs, also play roles in cancer pathways, gene regulation, and immune-related processes.
Consistent with the miRNA links identified, we used Cytoscape to search for miRNA- mRNA networks of GATA3 and 
SOX9 in DLBCL and LIHC, respectively, as two examples of such networks (Additional file 5: Fig. S4). GATA3 associated with 
TCGA data for DLBCL (GO enrichment q-value = 6.55). Also, a negative correlation of GATA3 with hsa-mir-431 (p-value 
= 4.9−E07, correlation = − 0.65) and hsa-mir-433 (p = 3.33E−5, correlation = − 0.566) was observed (Additional file 5: 
Fig. 3  Gene expression analysis of MES TFs in 31 cancer types. A Expression of TFs in cancer types based on TCGA records in comparison 
to matched normal tissue: significant overexpression in TCGA over normal tissue is displayed in red, while overexpression in normal tissue 
compared to TCGA data are displayed in green. B PRRX1 is significantly overexpressed in TCGA samples for diffuse large B cell Lymphoma 
(DLBCL), pancreatic adenocarcinoma (PAAD), thymoma (THYM) and stomach adenocarcinoma (STAD) tumours compared to normal sam-
ples expressed in log2 (TPM + 1), C PRRX1 gene expression fold change in TCGA in comparison to normal samples. The parameters for this 
analysis were set as Log2FC cut-off of 1 and p-value < 0.01. One-way ANOVA was used to test for differences in expression between normal 
and cancer tissue. D Expression of TFs in cancer types based on TCGA records in comparison to matched normal tissue, significant overex-
pression in TCGA over normal is displayed in red, while overexpression in normal over TCGA is displayed in green. E ASCL1 is significantly 
overexpressed in TCGA samples for glioblastoma multiforme (GBM), low grade glioma (LGG) and thymoma (THYM) tumours compared to 
normal samples expressed in log2 (TPM + 1), F ASCL1 gene expression fold change in TCGA in comparison to normal samples. The param-
eters for this analysis were set as Log2FC cut-off of 1 and p-value < 0.01. One-way ANOVA was used to test for differences in expression 
between normal and cancer tissue
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Fig. S4B). Closer inspection of the network also revealed the presence of ASCL1, another member of the MES CRC TFs, 
which also displayed negative regulation with hsa-mir-431 (p = 3.58E−6, correlation = − 0.61), hsa-mir-432 (p = 1.7E-4, 
correlation = − 0.52) and hsa-mir-433 (p = 1.48E–5, correlation=− 0.58) (Additional file 5: Fig. S4C). hsa-mir-433, a tumour 
suppressor in breast cancer, inhibits the growth of cancer cells by affecting cell migration [59]. Similarly, SOX9 was associ-
ated with TCGA data for LIHC (miRNA vs RNA) (GO enrichment q-value = 6.75) (Additional file 5: Fig. S4D). SOX9 positively 
correlated with hsa-mir-429 (= 4.03E−32, correlation = 0.56), hsa-mir-200a (p = 1.54E−32, correlation = 0.56) and hsa-
mir-200b (p = 3.8E−30, correlation = 0.54) (Additional file 5: Fig. S4E). The role of hsa-mir-429 as a biomarker of cancer 
initiation and progression for breast cancer has been previously validated, and, similarly, the mir-200 family members 
have been reported as potential prognostic biomarkers in multiple cancers [60, 61]. Collectively these results suggest 
the intricate connectivity of genes such as GATA3 and SOX9 that play essential roles in NB differentiation and neural 
crest development, respectively, with networks of miRNAs. These miRNAs have prognostic value in various cancers and 
should be investigated further in NB [13]. In Table 1, we have provided examples of the predicted prognostic potential 
of the 38 TFs with NB risk groups and patient survival in NB and other cancers.
Finally, we used the dbCoRC database to integrate mRNA expression of core TFs with their reconstructed circuitry in 
cancers. For instance, SMAD3 was indicated in the CRC of representative cell lines of DLBCL, colorectal cancer, pancreatic, 
hepatocellular carcinoma, breast, and gastric cancers (Table 2). These results suggested similarities in transcriptional 
regulatory mechanisms governed by these TFs in various cancer types [44], hence pointing towards the versatility and 
commonalities of these networks in cancers. These core TFs may display similar or contrasting diagnostic and prognostic 
values, a result warranting further investigation and validation.
4  Discussion
Core regulatory circuitries can regulate lineage or cell-specific gene expression and thereby confer a specific identity. 
These CRCs comprise super enhancers that are marked with high deposition of permissive H3K27 acetyl histone marks 
that drive a set of highly regulated TFs, which in turn self-regulate and regulate the expression of other TFs within the 
CRC [8–11].
Two specific cell identities have been identified in NB tumours; ADRN and MES, the latter bearing higher therapy 
resistance and being enriched in relapsed samples [5–7]. Despite conferring specific yet interconvertible cell identities 
in a rare paediatric cancer by the 38 MES and ADRN TFs, we were intrigued to study these TFs in both NB and the wider 
context of cancers to assess their potential as indicators of disease prognosis, progression, and relapse. Accordingly, 
MES-specific minimal residual disease (MRD) markers in NB were identified as PRRX1, EMO3, and POSTN in previous 
studies [62]. The detection of the mRNA of these genes in peripheral blood was effectively used for assessing MRD and 
correlated with low OS and DFS in NB patients, collectively suggesting the potential use of PRRX1 as a biomarker for 
prognosis, treatment, and remission in NB [62]. On a similar note, in several reports, GATA2 was shown to be associated 
with low-risk disease and better NB patient prognosis [63, 64], while EYA1 was expressed in earlier stages of NB [24]. 
Given this background, we aimed to dissect such links more comprehensively in NB and other cancers, specifically from 
the perspective of MES- and ADRN-specific CRC TFs. To that end, the extended list of MES and ADRN genes were initially 
subjected to cBioportal for NB samples retrieving identified genetic alterations with unknown or predicted oncogenic 
functions, including amplification, missense, in-frame, and truncating mutations, in addition to fusions and deletions in 
853 genes, with the vast majority bearing very low mutation rates per sample (< 0.5%). The identification and study of 
potential drivers in cancers will not only lead to the greater dissection of genomic alterations but may also inform future 
diagnostic and therapeutic studies. Gene Ontology enrichment studies revealed the enrichment of JAK/ STAT signalling 
for the MES gene list perhaps suggesting a requirement for the signalling input from this pathway in cell proliferation, 
Fig. 4  Kaplan Meier curves for cumulative survival, OS and DFS in cancer patients. The outcome of CREG1, SIX1 and MEOX1 expression in 
patients with KIRP and UCEC using Kaplan Meier curves. A For KIRP: CREG1 (HR = 1.52, p = 0.0217), SIX1 (HR = 2.04, p = 0.00046), and MEOX1 
(HR = 2.25, p = 0.00098 were obtained), B for UCEC: CREG1 (HR = 1.32, p = 0.048), SIX1 (HR = 1.85, p = 0.0001), and MEOX1 (HR = 1.43, p = 0.0079) 
were obtained (red and blue lines representing increased and reduced expression in patients, respectively). In all cases, increased expres-
sion of these genes correlates with reduced cumulative survival of patients. C–E OS and DFS Kaplan Meier curves generated by GEPIA2 for 
ACC patients for CBFB (top: log-rank test p = 4.9E-06, HR = 7.5, p(HR) = 7.2E-5 and bottom: log-rank test p = 0.00023, HR = 3.7, p(HR) = 0.00056), 
SOX11 (top: log-rank test p = 0.00032, HR = 5.2, p(HR) = 0.0012 and bottom: log-rank test p = 0.00037, HR = 3.7, p(HR) = 0.00088), and ISL1 (top: 
log-rank test p = 4.4E-05, HR = 6.3, p(HR) = 0.00033 and bottom: log-rank test p = 0.00031, HR = 3.7, p(HR) = 0.00073) revealing significant 
decreases in OS and DFS for patients. HR = Hazard risk
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tumourigenesis, and migration [65–70]. Furthermore, we elected to focus on the list of 20 MES and 18 ADRN CRC TFs, ini-
tially testing the expression of MES and ADRN genes with NB risk levels. This study revealed that ADRN-associated SATB1, 
GATA2, TFAP2B, KLF13, KLF7, and PBX3 were downregulated in high-risk NB cases, while SIX3 and GATA3 were upregulated 
in this group. Similarly, MES-associated MEOX1, CBFB, and DCAF6 genes were downregulated in high-risk NB cases, while 
SMAD3, ID1, SOX11, ZNF217, and EGR3 were upregulated. Evidence supports the potential of GATA2 as an early cancer 
detection marker and a good prognostic factor in NB, with high GATA2-expressing patient groups displaying greater 
OS compared to those with low levels of GATA2 [22, 63, 64]. Consistently, we showed that GATA2 was downregulated in 
high-risk NB. Consistently, ID1, SOX11, TFAP2B, KLF7, and GATA3 were linked to neurogenesis or NB differentiation [13, 
18, 19, 23, 71, 72], but to our knowledge, these studies did not discuss their association with survival and risk groups in 
NB, hence our findings are novel.
Evidence suggested the importance of lncRNAs in NB risk group stratification, leading us to compare the network 
formed by the 38 TFs and lncRNAs expression [46]. We identified that DBH-AS1 expression was strongly associated with 
TFAP2B and GATA2. Furthermore, its expression was lower in high-risk NB and was associated with better prognosis. 
In keeping with these data, the downregulation of DBH-AS1 in osteosarcoma was shown to be an indicator of good 
prognosis in these patients [73], amongst other reports in the literature highlighting the significance of this lncRNA in 
various cancers [48, 74].
Given the connection between the 38 TFs and the reported lncRNAs in other cancers [48–51], we elected to expand 
our investigation to other cancers. We used several bioinformatic tools, including GEPIA2, TIMER2, Omicsnet, Cytoscape, 
and dbCoRC to gain a deeper understanding of the role of these TFs in other cancers including their overexpression, 
prognostic value, association with cells of the TME, miRNA-TF network connectivity, and utility in other CRCs. Both MES 
and ADRN TFs displayed patterns of overexpression in TCGA tumour samples compared to matched normal samples. For 
Fig. 5  Prognostic summary and immune cell infiltration associated with MES and ADRN TFs. A Data obtained from the human pathology 
atlas reveals a significant association between the expression of MES and ADRN TFs providing either favourable or unfavourable predic-
tive value in various cancers as indicated (pink and blue colours represent unfavourable and favourable prognosis, respectively). The clas-
sification of favourable and unfavourable prognosis in this database, is based on calculated survival probability expressed in respective 
Kaplan Meier curves. B Positive association between EGR3 expression with CAF infiltration in the TME in KIRP (p = 7.67E-08, Spearmann’s 
Rho = 0.327), C PAAD (p = 2.54E-05, Spearmann’s Rho = 0.316) and D STAD (p = 1.24E-10, Spearmann’s Rho = 0.323). For all plots, EPIC estima-
tions for expression are displayed as log2 TPM and were adjusted for tumour purity. EPIC estimations allowed for the comparison of cell 
types within a sample and provided scores for cell fractions. CRC = Core regulatory circuitry, TF = Transcription Factor
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Fig. 6  Network connectivity of MES and ADRN TFs. A GATA3 and GATA2 display the highest degree of connectivity with 38 and 19 connec-
tions, respectively. B KEGG gene enrichment analysis reveals enrichment for ‘immune’ and ‘miRNA’ in cancer terms. C SMAD3, SOX9, WWTR1 
and IFI16 have 32, 23, 6 and 5 connections, respectively, D KEGG gene enrichment analysis revealed enrichment for ‘breast cancer’, ‘prostate 
cancer’ and ‘hepatocellular cancer’ in addition to ‘miRNAs in cancer’ terms
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instance, MES-specific PRRX1 (sufficient to convert ADRN to MES subtypes) [5, 6] was overexpressed in tumour samples 
compared to matched normal tissue of multiple cancers including low-grade glioma, GBM, DLBCL, STAD, PAAD, and THYM. 
Consistent with this finding, the role of PRRX1 in promoting stemness and angiogenesis in glioma has been reported 
[75]. In our study, ADRN-specific GATA3 was overexpressed in breast invasive carcinoma (BRCA), cervical squamous cell 
carcinoma and endocervical adenocarcinoma (CESC), testicular germ cell tumours (TGCT), STAD, PAAD, and THYM, data 
that we matched with the mutational profiles of these genes. Consistent with these findings, the predictive value of 
SMAD4/GATA3 for OS and relapse-free survival (RFS) for breast invasive ductal carcinoma has been reported in previous 
studies with SMAD4-/GATA3+ patients displaying better OS and RFS [76].
The association of these TFs with lower survival was determined using the TIMER2 tool across various cancer types. For 
more than half of the MES and ADRN TFs (e.g., SIX1, MEOX1, and ZNF536), decreased cumulative survival was observed 
for two cancer types in particular; KIRP and UCEC, but to a lower extent in other cancers, indicating the influence of 
these TFs on patient survival in these cancers. Consistently, the high expression of SIX1 in endometrial cancer could be 
a predictor of unfavourable prognosis in these patients [77]. Similarly, higher Spearman’s risk and reduced survival were 
observed for LGG, STAD, mesothelioma (MESO), pheochromocytoma and paraganglioma (PCPG), and thyroid carcinoma 
(THCA) patients expressing SIX1, collectively suggesting the prognostic value of SIX1 in these cancers. On a similar note, 
a significant association between the expression of ELK4, CBFB, IFI16, PRRX1, AEBP1, and GATA3 with an unfavourable 
outcome in renal cancer has been identified in previous reports [78, 79]. In light of these findings, the most significant 
result obtained in this study is the potential prognostic values of the 38 TFs across the cancer types reported in Table 1.
We next investigated the association between MES and ADRN TFs with the infiltration of cells associated with cells in 
the TME including Treg, CAFs, ECs, B cells, and gamma-delta T cells. We found a positive correlation of MES and ADRN TFs 
with the infiltration of CAFs and ECs in KIRP, PAAD, STAD, and THYM. Recent studies have suggested that CAFs produce 
growth factors and cytokines that may facilitate angiogenesis, promote tumour growth and modulate cancer stem cell 
characteristics [80]. In keeping, the role of CAFs in promoting angiogenesis in gastric cancer has previously been reported 
[81]. We also found strong correlations between MES and ADRN TFs with markers of cancer cell stemness and cancer 
cell motility including CDH1, CDH2, NANOG, SOX2, TWIST1, VIMENTIN, and Fibronectin across cancers. For instance, we 
found positive correlations between SOX9 and SATB1 with these markers in colon adenocarcinoma (COAD) and lung 
adenocarcinoma (LUAD), respectively. Accordingly, SATB1 promotes metastasis and cell growth in colorectal cancer 
[82]. In another study, TGF-β secreted by TAMs was shown to promote metastasis in non-small cell lung cancer (NSCLC) 
through promoting TGF-β/SOX9 axis expression [83]. These observations suggest that MES TFs may be associated with 
genes that mediate tumour cell motility and metastasis.
Network connectivity followed by KEGG term enrichment of MES TFs revealed that the extended network of genes 
linked to TFs such as SMAD3, IFI16, and SOX9 was also involved in various cancer regulatory pathways, cancer types, and 
transcriptional misregulation, while the extended network of GATA2 and GATA3 connected genes has roles in various 
immune pathways and miRNAs in cancers. Recent studies have shown that SMAD3 can have a dual role in repressing and 
promoting cancer by inhibiting cell proliferation and regulating transcriptional output favouring metastasis, respectively 
[84]. On the other hand, a study identified GATA3 upregulation and its association with favourable outcomes in breast 
cancer [85]. Moreover, we reveal that both GATA3 and SOX9 are negatively and positively associated with hsa-mir-433 
in DLBCL and hsa-mir-429 in LIHC, respectively, suggesting crucial CRC TFs may overlap in function in various cancer 
types, govern similar regulatory networks, and display similar roles as disease biomarkers and prognostic predictors. 
Finally, we show that SMAD3, ZNF217, KLF13, GATA2, GATA3, KLF7, and PHOX2B are components of CRCs in other cancers, 
Table 2  The integration of 
network connectivity of MES 
and ADRN TFs in CRCs of other 
cancers
CRC TF (MES or 
ADRN)
Utility of TF in cancers (an example of a corresponding cell line) determined in this study
SMAD3 DLBCL (SU-DHL-6), colorectal cancer (HCT-116), pancreatic cancer (MiaPaca2), hepato-
cellular carcinoma (HepG2), breast cancer (MDA231), gastric cancer (MKN7)
ZNF217 Breast cancer (MDA231), colorectal cancer (HCT-15), gastric cancer (T980436)
KLF13 Gastric cancer (T2001206), small cell lung cancer (NCI-H69)
GATA2 Prostate cancer (LNCaP)
GATA3 Breast cancer (MCF7)
KLF7 Gastric cancer (T2000085), small cell lung cancer (NCI-H69)
PHOX2B Small cell lung cancer (NCI-H82)
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including DLBCL, pancreatic, gastric, breast, and small cell lung cancer. These data suggest similarities between CRCs 
and transcriptional regulatory circuitries across the malignant spectrum and that these key TFs, embedded in similar 
networks in various cancers, may display valuable diagnostic and prognostic factors [86].
5  Conclusions
In conclusion, this study provides an overview of the implications of MES and ADRN TFs in NB risk groups and patient 
survival, and reveals their extended networks formed with miRNAs and lncRNAs. We also provide a pan-cancer view of 
the network connectivity and utility of these TFs in gene networks in other cancers and their correlation with DFS and 
OS, association with immune cell infiltration and stemness, and EMT markers. Our meta-analysis reveals the pan-cancer 
implication of the NB MES and ADRN TFs and their roles as putative prognostic predictors in various cancers. A better 
understanding of these genes in both NB and other cancers may pave the way to discovering specific biomarkers of 
disease progression, treatment response, and remission in these cancers, impacting patient survival and quality of life.
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